• Mashup Score: 0

    John Mandrola, MD, interviews Andrew Foy, MD, about his meta-analysis of major cardiovascular trials looking at patients with higher comorbidity burden to see if they experience treatment benefits.

    Tweet Tweets with this article
    • .@drjohnm interviews @AndrewFoy82 about his meta-analysis of major cardiovascular trials looking at patients with higher comorbidity burden to see if they experience treatment benefits. #ACC23 #WCCardio #CardioTwitter https://t.co/93prjzUaLP

  • Mashup Score: 0

    Black patients with cancer are significantly more likely to experience heart damage following chemotherapy than White patients are, a research review indicates.

    Tweet Tweets with this article
    • A research review shows Black cancer patients are more likely to experience cardiotoxicity and congestive heart failure related to chemotherapy. https://t.co/k6OtbHImsI #MedTwitter #ACC23 #WCCardio

  • Mashup Score: 1

    ACC Anywhere provides easy access to all of ACC’s video content in one location. You can easily search and browse presentations and watch Collections anytime, anywhere with on demand access. Collection ACCSAP Session Featuring This Year’s CMP Topic Part 1: Test Yourself With Questions on Valvular Heart Disease ACCSAP Session Featuring This Year’s CMP Topic Part 1: Test Yourself With Questions…

    Tweet Tweets with this article
    • Get on-demand access to #ACC23/#WCCardio's Stump the Chump session where some of the best minds in pediatric & #CHD battle over the toughest congenital case. Hear their thought processes, how they use available data, & more w/ ACC Anywhere. 🔎 https://t.co/MF5pm2jR48 https://t.co/T89qT3DKQj

  • Mashup Score: 0

    Ileana Piña, MD, MPH, and Barry A. Borlaug, MD, discuss the CAMEO-DAPA study in patients with HFpEF and potential mechanisms of action for SGLT2 inhibitors.

    Tweet Tweets with this article
    • Ileana Piña, MD, MPH, and Barry A. Borlaug, MD, discuss the CAMEO-DAPA study in patients with HFpEF and potential mechanisms of action for SGLT2 inhibitors. #ACC23 #WCCardio https://t.co/AAHGveWuh4

  • Mashup Score: 5

    The 3-year results show that low-surgical-risk patients undergoing aortic valve replacement continue to show lower rates of all-cause mortality and disabling stroke with TAVR compared with surgery.

    Tweet Tweets with this article
    • “The results provide a little more reassurance…that will go a little way further," #JACCINT Editor-in-Chief Dr. David Moliterno commented on the 3-year results from the Evolut trial at #ACC23/#WCCardio. Read more in @Medscape: https://t.co/jDT7t3YMJs @JACCJournals #TAVR

  • Mashup Score: 0

    Patients with hypertrophic cardiomyopathy should no longer be routinely saddled with restriction from intense exercise or sports, which don’t add to their arrhythmic risk, a large study suggests.

    Tweet Tweets with this article
    • The message of the LIVE-HCM study at #ACC23/#WCCardio "will be that everyone needs to exercise, and that at whatever level you want to do it, it's relatively low risk,” said #ACCSportsCardio Immediate Past Chair Dr. @eugenechung01. Read more in @Medscape: https://t.co/6JZZhQseek

  • Mashup Score: 0

    Cardiology clinics receiving educational and advisory guidance improved their treatment of patients with type 2 diabetes and atherosclerotic disease.

    Tweet Tweets with this article
    • "A particular strength of this study was its simple design. All the interventions are low-tech and scalable," #ACCCVT member @KristenPharmD commented on the COORDINATE-Diabetes trial at #ACC23/#WCCardio. https://t.co/btjnyGA5R9 #Diabetes